BioPharmX (BPMX) to participate in the ROTH Capital Partners Conference in Orange County, California, Sunday, March 11, 2018
Tuesday, March 13, 2018
ROTH is an annual event allowing small and mid-cap company executives to pitch their companies to investors.
This gathering of institutional investors, private equity investors, VCs and executives, and service providers has become a must-attend event for anyone working in the small and mid-cap space.
February 27, 2018, BioPharmX announced, "We're excited to learn that the USPTO granted another patent in the BPMX microparticle family for our encapsulation delivery system!"
In an interview March 31, 2017 BioPharmX Chief Financial Officer Greg Kitchener had this to say,
"The way to think about BPX-01 is that we're providing a very unique approach to how minocycline is delivered. What differentiates us further from other competitors is that our delivery system is a hydrophilic delivery system, as opposed to the more traditional lypophilic formulation. Lypophilic means, essentially, oil-based, and as you probably know, oil and acne don't go well together. It's occlusive, it doesn't feel good on your skin.
"We're able to stabilize the drug," Kitchener continued, "we're able to fully solubilize the drug. That's very different and unique, no one's really been able to do that with minocycline yet. What that means is that we're able to improve our bio-availability, and also able to use a very low dosage of minocycline.
"We think we'll do very well from an efficacy standpoint, compared to both the orals as well as other topicals. Because we're able to use a low dosage of it, our safety profile is much improved over anything out there."
The U.S. market alone for prescription acne medications is estimated at $4 billion, according to a BioPharmX press release.
